Women with psoriatic arthritis achieve fewer therapeutic goals
Compilation
psoriasis arthritis (AP) According to the latest EPISER study carried out by the Spanish Society of Rheumatology, approximately 230,000 people suffer from this disease in Spain and its prevalence is 0.58%. (BE). This heterogeneous chronic inflammatory disease affects men and women differently. In fact, it is women who typically respond less well to treatments that are less aggressive than men.
In addition, women have more intolerances, side effects, and lower adherence to treatment than men. This is partly due to delays in diagnosis. Dr. Mª Luz Garcia VivarHead of the Department of Rheumatology, Basurto University Hospital, during the VIII SER Seminars on Psoriatic Arthritiswhich took place on April 26 and 27 together with Johnson & Johnson.
Dr. García Vivar emphasized that “One of the tasks of multidisciplinary units is to improve the late diagnosis of patients with psoriatic arthritis” because, according to a survey conducted among patients of the association Action for psoriasisIt is estimated that diagnosis may take about four years.
Dr. Mª Luz García Vivar: “There are studies that have shown a six-month delay in diagnosis in women with psoriatic arthritis.”
In its turn, Dr. Eva Galindezrheumatologist at Basurto University Hospital and coordinator of these training seminars, insisted that “Early detection and diagnosis of patients, as well as effective disease control remain unmet medical needs for this pathology. Moreover, predicting treatment response also remains a challenge for rheumatologists.”
The differences that exist between men and women in the perception of this disease are obvious. However, they are not analyzed with the frequency and depth that are recommended regulation of gender issues in research. Dr. Garcia Vivar noted that several studies “found a six-month delay in diagnosis in women” In this regard, there are international initiatives to examine gender differences in disease and treatment behavior, which is expected to provide new evidence to aid optimal management, including in women with PsA.